122 related articles for article (PubMed ID: 27793952)
1. New Drug and Possible New Toxicity - Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors.
Inayat F; Saif MW
Anticancer Res; 2016 Nov; 36(11):6201-6204. PubMed ID: 27793952
[TBL] [Abstract][Full Text] [Related]
2. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
Ben Ami E; Demetri GD
Expert Opin Drug Saf; 2016; 15(4):571-8. PubMed ID: 26865352
[TBL] [Abstract][Full Text] [Related]
3. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
Rehman H; Hakim N; Sugarman R; Seetharamu N; Saif MW
J Oncol Pharm Pract; 2020 Sep; 26(6):1511-1515. PubMed ID: 32067560
[TBL] [Abstract][Full Text] [Related]
4. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
[TBL] [Abstract][Full Text] [Related]
5. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
6. Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate.
Fujii M; Iwasaki T; Takahashi I; Kishiyama K; Honma M; Takahashi H; Ishida-Yamamoto A; Iizuka H
J Dermatol; 2015 Mar; 42(3):338-9. PubMed ID: 25580575
[No Abstract] [Full Text] [Related]
7. Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
Paolino G; Didona D; Clerico R; Corsetti P; Ambrifi M; Bottoni U; Calvieri S
Cutis; 2016 Jun; 97(6):E12-6. PubMed ID: 27416091
[TBL] [Abstract][Full Text] [Related]
8. A rare case of cardiac toxicity in a patient with imatinib treatment: Case report.
Samanci NS; Guliyev M; Degerli E; Celik E; Turna ZH
J Cancer Res Ther; 2022; 18(3):792-794. PubMed ID: 35900559
[TBL] [Abstract][Full Text] [Related]
9. Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
Reichardt P; Schlemmer M; Delgado Perez JR; Papai Z; Prausova J; Melichar B; Fumagalli E; Barone C; Bauer S; Pustowka A; Crippa S; Castellana R; Quiering C; Le Cesne A
Oncol Res Treat; 2019; 42(12):629-635. PubMed ID: 31550719
[TBL] [Abstract][Full Text] [Related]
10. [Acute Promyelocytic Leukemia Developed during Imatinib Therapy for Gastrointestinal Stromal Tumors].
Yu YP; Song P; Mei JG; An ZM; Zhou XG; Li F; Wang LP; Tang YM; Zhai YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):358-364. PubMed ID: 28446275
[TBL] [Abstract][Full Text] [Related]
11. Imatinib-induced agranulocytosis in patients with gastrointestinal stromal tumors.
Farag S; Verschoor AJ; Bosma JW; Gelderblom H; Kerst JM; Sleijfer S; Steeghs N
J Clin Pharmacol; 2015 Aug; 55(8):920-5. PubMed ID: 25810235
[TBL] [Abstract][Full Text] [Related]
12. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
Ferraresi V; Catricalà C; Ciccarese M; Ferrari A; Zeuli M; Cognetti F
Anticancer Res; 2006; 26(6C):4771-4. PubMed ID: 17214339
[TBL] [Abstract][Full Text] [Related]
13. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
[TBL] [Abstract][Full Text] [Related]
15. Erythroderma: An unusual manifestation of imatinib - A rare case report.
Kataria P; Patel A; Kendre P; Tahiliani N; Mule T; Bohra M
J Cancer Res Ther; 2022; 18(1):253-256. PubMed ID: 35381793
[TBL] [Abstract][Full Text] [Related]
16. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
[TBL] [Abstract][Full Text] [Related]
17. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
18. A successful approach to overcome imatinib-induced skin toxicity in a GIST patient.
Desar IM; van Herpen CM; van Erp NP; Kaal SE; van de Kerkhof PC; van der Graaf WT
Anticancer Drugs; 2016 Jul; 27(6):576-9. PubMed ID: 26982239
[TBL] [Abstract][Full Text] [Related]
19. EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib.
Bouché O; Cesne AL; Rios M; Chaigneau L; Italiano A; Duffaud F; Lecomte T; Arsène D; Manfredi S; Aparicio T; Remy S; Isambert N; Collard O; Priou F; Bertucci F; Sambuc R; Bisot-Locard S; Bourges O; Chabaud S; Blay JY
PLoS One; 2018; 13(9):e0204117. PubMed ID: 30226855
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
